Ellie Kelepouris, MD

Emerging Therapies: a look at the current data: NefIgArd study

), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?

Videos

Biomarkers and clinical indicators play a crucial role in predicting disease outcomes, offering insights into disease progression, treatment response, and patient prognosis. These indicators can be genetic, molecular, or cellular, and are often identified through advanced diagnostic techniques. For instance, specific gene mutations or protein expressions can indicate the likelihood of disease recurrence or metastasis. Additionally, clinical indicators such as tumor size, stage, and patient health status are integral in assessing outcomes. Personalized medicine leverages these biomarkers to tailor treatment plans, enhancing therapeutic efficacy and patient survival rates.

Panelists discuss how the NefIgArd study findings contribute valuable insights into the efficacy of emerging therapies for IgA nephropathy, emphasizing their role in reducing proteinuria and improving patient outcomes.

Emerging Therapies: a look at the current data: PROTECT study

Panelists discuss how the PROTECT study’s results enhance the understanding of emerging therapies for IgA nephropathy, focusing on their potential to reduce proteinuria and modify disease progression.

Emerging Therapies: a look at the current data: APPLAUSE

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

Emerging Therapies: a look at the current data: ALIGN

Ellie Kelepouris, MD

Articles